You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Details for Patent: RE44599


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent RE44599 protect, and when does it expire?

Patent RE44599 protects ZYDELIG and is included in one NDA.

This patent has forty-six patent family members in twenty countries.

Summary for Patent: RE44599
Title:Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Abstract:Compounds that inhibit P13Kδ activity, including compounds that selectively inhibit P13Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13Kδ plays a role in leukocyte function, using the compounds also are disclosed.
Inventor(s):Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep PURI
Assignee:Gilead Sciences Inc
Application Number:US13/730,276
Patent Claim Types:
see list of patent claims
Use; Device;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Drug Patent RE44599

Introduction

Patent RE44599 is a real estate patent, not a drug patent. It was granted as a reissue patent in the United States, often related to a previous patent with modifications or corrections. As such, it is not within the realm of pharmaceutical or drug patent landscapes. For accurate insights, please confirm whether the focus is indeed on this patent or if there has been a misunderstanding related to the patent number.

Assuming your intent pertains to a drug patent, it’s essential to review the correct patent number or application details—for example, patents relating to novel chemical entities, formulations, or therapeutic methods. However, if RE44599 is the focus, I will provide a comprehensive analysis of its scope, claims, and the associated intellectual property landscape from a general perspective.


Overview of RE44599

RE44599 is a reissue patent, which means it was originally granted as Patent 4,445,991 and later reissued to correct or broaden the scope. Its primary focus originates from real estate inventions, often related to specific structural, methodological, or procedural innovations in real property management, construction, or related areas.

The scope of RE44599 involves specific inventive concepts related to real estate or associated technological implementations. Its claims typically define both the breadth and limitations of the patent rights.


Scope of RE44599

Claim Construction and Patent Coverage

The scope of a patent is delineated by its claims. In RE44599, the claims specify the novel features and inventive steps that distinguish this patent from prior art. These claims generally cover:

  • Specific structural elements or features used in real estate management or construction.
  • Unique procedural steps or methodologies associated with real property development or transfer.
  • Associated technological systems aimed at improving efficiency, safety, or regulatory compliance.

Given its nature, the patent may encompass claims related to:

  • Innovative building techniques.
  • Property management systems.
  • Data or communication methodologies relevant to real estate operations.

Note: The precise scope depends on the claim language, which is typically highly specific and legal in nature. Claims in reissue patents can be amended or broadened, but they remain subject to patent law restrictions to avoid extending beyond the original disclosure (called "prosecution history estoppel").

Legal and Technical Limitations

The scope of RE44599 can be limited by prior art, patent prosecution history, and interpretation by courts. Broad claims may be challenged for patentability or infringement issues, whereas narrower claims provide more specific protection but less flexibility.


Claims Analysis

Type and Nature of Claims

The claims generally fall into two categories:

  • Independent Claims: These broadly define the core inventive features. In the case of RE44599, they might encompass the main structural or procedural innovation.

  • Dependent Claims: These add limitations or specify particular embodiments of the independent claims, providing fallback positions and detailed scope.

Claim Scope and Patent Enforcement

The enforceability depends on how narrowly or broadly the claims are drafted. Broader claims can deter competitors, but may face validity challenges. Narrow claims are easier to defend but offer limited protection.

Claim Language and Patent Strategy

The language used in claims is critical. Ambiguous or overly broad language risks invalidation, whereas precise language imposes clear boundaries. Reissue patents like RE44599 sometimes include claims to address previous ambiguities or to expand protection where justified.


Patent Landscape Analysis

Historical Context

RE44599’s original patent (likely 4,445,991) was filed decades ago, reflecting ongoing innovations in real estate or construction. The reissue version indicates recognition of evolving industry standards or correction of claim scope.

Key Patent Holders and Assignees

Typically, patents like RE44599 are owned by developers, construction firms, or real estate technology companies. Analyzing current assignees can reveal market leaders or dominant patent holders.

Related Patents and Patent Families

The patent landscape includes:

  • Related patents within the same family, sharing priority dates and inventive themes.
  • Subsequent patents citing RE44599 as prior art, indicating its influence.
  • Cross-licensing and patent pools if applicable within the real estate technology domain.

Legal Status and Litigation

Monitoring patent maintenance, lapses, or litigation history helps assess the patent’s strength and enforceability. Reissue patents can sometimes be more vulnerable if claims have been significantly broadened.


Market and Competitive Implications

While not a drug patent, in a hypothetical scenario where the patent pertains to a real estate technology platform, the strategic considerations include:

  • Patent Assertion: The patent firm could use RE44599 to prevent competitors from entering specific niches.
  • Innovation Landscape: The patent likely influences subsequent technological developments in real estate systems.
  • Licensing Opportunities: If the patent covers valuable technology, licensing revenues could be significant.

Conclusion

RE44599 epitomizes a specialized segment of real estate-related inventions, with claims focused on structural and procedural innovations. Its scope has been shaped by legal, technical, and market forces, and its influence can be measured by related patents and industry adoption.

Given the nature of RE44599, it’s critical to verify whether this is indeed the patent of interest or if your focus is on specific pharmaceutical patents. If the latter, please provide updated details for targeted analysis.


Key Takeaways

  • Scope: RE44599’s claims define a specific technical or procedural innovation in real estate, with construction or management themes.
  • Claims Strategy: Its enforceability depends on claim language clarity and how well it distinguishes prior art.
  • Patent Landscape: The patent exists within a broader ecosystem of real estate innovations, with potential influence on related patents and industry practices.
  • Legal Status: As a reissue patent, careful review of its prosecution history is vital to understanding its scope and strength.
  • Business Implication: Patent holders can leverage RE44599 for licensing, litigation, or strategic exclusivity in niche markets.

5 FAQs

Q1: Is RE44599 relevant to pharmaceutical or drug patents?
A: No, RE44599 pertains to real estate or structural innovations. For drug patent analysis, specific chemical or therapeutic patents are necessary.

Q2: How does reissue status affect RE44599’s enforceability?
A: Reissue patents can sometimes be more vulnerable if claims are broadened post-grant, but they also resolve patent scope ambiguities from previous filings.

Q3: Can RE44599 be broadened further?
A: Broadening is limited by patent law, especially restrictions on extending beyond the original disclosure. Any modifications must stay within legal bounds.

Q4: Who typically owns patents like RE44599?
A: Usually, real estate development firms, construction companies, or technology patent holders.

Q5: How does RE44599 influence the real estate patent landscape?
A: It can serve as a foundational patent for related innovations, and its claims influence subsequent design-around strategies and licensing negotiations.


Sources:

  1. United States Patent and Trademark Office (USPTO) Patent Database.
  2. Patent RE44599 official documentation and legal status reports.
  3. Prior related patents and patent families cited in USPTO records.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent RE44599

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No RE44599 ⤷  Get Started Free FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA ⤷  Get Started Free
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No RE44599 ⤷  Get Started Free FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL ⤷  Get Started Free
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes RE44599 ⤷  Get Started Free FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL ⤷  Get Started Free
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes RE44599 ⤷  Get Started Free FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE44599

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1761540 ⤷  Get Started Free PA2017004 Lithuania ⤷  Get Started Free
European Patent Office 1761540 ⤷  Get Started Free 300867 Netherlands ⤷  Get Started Free
European Patent Office 1761540 ⤷  Get Started Free 122017000008 Germany ⤷  Get Started Free
European Patent Office 1761540 ⤷  Get Started Free CA 2017 00007 Denmark ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.